Under the 12-month project, Jellagen will use funding in R&D to develop a new method for functionalizing jellyfish collagen to tackle two main clinical issues associated with chronic wounds, including sepsis and maintaining healthy blood flow to the site of injury.
Jellagen CEO Andrew Mearns Spragg said: "We’re delighted to have been awarded this grant from Innovate UK. The grant will help support key research & product development activities within Jellagen and crucially offers the ability to widen our product and IP portfolio.
"Wound care represents an exciting market opportunity for the business and chronic ulcer treatments remain an unmet clinical need when it comes to effective treatments."
The project will assess biological activity in models of wound healing targeting chronic wounds such as diabetic foot ulcer (DFU).
Jellagen has collaborated with University of Highlands and Islands (UHI), Neem Biotech, Syncura, Welsh Wound Innovation Centre and University College London (UCL) for the project to develop new intellectual property and wound care products.
Jellagen, along with its strategic partner Collagen Solutions, also intends to produce a GMP certified jellyfish collagen product as a raw material for use in medical devices.
